Alopecia is the common autoimmune disorder, which causes hair loss or sometimes it may lead to baldness. Alopecia is classified into alopecia areata, androgenic alopecia, alopecia totalis, and cicatricial alopecia. Alopecia areata is a common autoimmune disorder that results in unpredictable hair loss. In this case, the body attacks its own anagen hair follicles and suppresses or stops hair growth. Cicatricial alopecia is the condition characterized by hair loss accompanied by the formation of scars.
Alopecia is the condition described for excessive hair damage or hair loss. Alopecia treatment plays a major role in advanced healthcare, as it aids in prevention of hair fall and regrowth of hair. The unhealthy lifestyle, ageing, and hormonal imbalance are some of the factors leading to alopecia condition.
To Get Download Sample Copy Of This Report:
https://www.coherentmarketinsights.com/insight/request-sample/1847
The global alopecia treatment market size was valued at US$ 7,325.0 million in 2017, and is expected to exhibit a CAGR of 4.9% over the forecast period (2018–2026).
Rising product launch and robust pipelines are expected to drive the global alopecia treatment market. For instance, in November 2018, Fidia Pharma launched Trinov hair growth lotion for hair growth in Italy. Furthermore, in September 2018, Eli Lilly and Company initiated phase 2 clinical trial to assess the safety and efficacy of Baricitinib drug in treating patients with alopecia areata. The study is estimated to complete in August 2022.

Rising initiatives such as crowdfunding campaigns and increasing collaboration by the market players is expected to bolster the market growth. For instance, in 2018, HairClone, a U.K. based company working on cellular hair restoration therapies, launched its public crowdfunding campaign. The company collaborated with Capital Cell, a crowdfunding company. Similarly, in May 2013, RepliCel Life Sciences Inc. and Shiseido Company, Limited announced collaboration and technology development transfer framework agreement for RepliCel’s RCH-01 hair regeneration technology.
To Get Download PDF Copy Of This Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1847
Increasing acquisition strategies in the region by the market players are major factor expected to propel the market growth. For instance, in August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., which expanded Aclaris’ inflammation and immunology pipeline with the addition of Confluence’s lead product candidates CDD-450, topical Janus kinase inhibitors, and IL2-inducible T-cell kinase inhibitor programs.
Moreover, collaboration of market players with regulatory authorities as well as other government organizations is further expected to support growth of the North America alopecia treatment market over the forecast period. For instance in April, 2019, Precision Therapeutics Inc., Helomics, and the National Alopecia Areata Foundation (NAAF), entered into an agreement to treat people affected by an autoimmune skin disease called alopecia areata. The agreement was intended to provide a next-generation patient registry to drive research on new treatments for people with this disease.
To Get More Information This Report:
https://www.coherentmarketinsights.com/market-insight/alopecia-treatment-market-1847
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
Contact Us:
Name: Mr. Raj Shah
Email: [email protected]
Phone: US +12067016702
Country: United States
Visit our Blog: https://hospitalhealthcareblog.wordpress.com/